Pincer Biotech appoints CEO, cementing goal to combat antibiotic resistance

The firm wants to develop treatments targeting certain types of antibiotic-resistant bacteria, and has recently brought in the founder of Expres2ion as chief executive, intensifying the firm’s work.
Charlotte Dyring, newly appointed CEO of Pincer Biotech | Photo: Privat / Charlotte Dyring
Charlotte Dyring, newly appointed CEO of Pincer Biotech | Photo: Privat / Charlotte Dyring
by albert rønning-andersson, translated by daniel pedersen

What are the most pressing medical challenges when it comes to developing new drugs against antimicrobial resistance (AMR)?

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading